Within the past week, researchers announced the results of two major clinical trials that could herald a new era in cancer treatment. Scientists are learning how to teach the immune system to fight cancer and, potentially, prevent certain cancers from developing in the first place. Their discoveries also challenge the way the Food and Drug Administration (FDA) evaluates new medicines.
On November 17, Memorial Sloan Kettering Cancer Center announced that an experimental vaccine significantly prolonged survival in patients with acute myeloid leukemia (AML), a deadly cancer of the blood and bone marrow. Six days earlier, The New England Journal of Medicinepublished the results of a clinical trial demonstrating that a personalized messenger RNA (mRNA) vaccine reduced the likelihood that melanoma, a potentially deadly form of skin cancer, would recur after surgery.